Regeneron Pharmaceuticals will sell potential Covid-19 prophylactic antibody at an internationally comparable price in the US to make it more affordable, as per a recent update on a deal with the US government.  

Under Project NextGen, Regeneron received government funds to develop an antibody therapy to prevent Covid-19. The US Department of Health and Human Services (HHS) has now revealed that any product that is commercialised from this public-private partnership will have a list price in the US that is equal or less than the retail price in other comparable markets.

Regeneron entered the Covid-19 market when it released its first antibody therapy REGEN-CoV (casirivimab and imdevimab), also known as Ronapreve, at a time when infection rates were still rising and most people were yet to receive booster doses, in August 2021.

Since then, several new variants of SARS-CoV-2 changed the potency of the antibody therapy, and it was eventually rendered ineffective against the Omicron variant. This resulted in the FDA amending the original emergency use authorisation to disallow its use in the US, in January 2022.

However, sales of the antibody continued in the rest of the world, where it is marketed by Roche, where it reported $613.2m in Q1, but none in the subsequent quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Project NexGen plan now provides Regeneron another chance to develop a prophylactic antibody against Covid-19, and this time with significantly more government funding. The US Department of Health and Human Services will cover upto 70% of the company’s costs to develop such an antibody, allowing for approximately a potential value of $326m in government funding.

Our signals coverage is powered by GlobalData’s Thematic Engine, which tags millions of data items across six alternative datasets — patents, jobs, deals, company filings, social media mentions and news — to themes, sectors and companies. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed.